C4 Therapeutics, Inc. CCCC 深 滬
等待開盤 11-26 09:30:00 美东时间
2.48
+0.020
+0.81%
華盛通- 最 高2.495
- 今 開2.47
- 成交量 87.31万股
- 最 低 2.42
- 昨 收 2.46
- 總市值 1.77亿
- 52周最高 5.10
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 1.085
- 委 比 38.70%
- 總股本 7117.08万
- 歷史最高 51.21
- 量 比 0.74
- 振 幅 3.05%
- 歷史最低 1.06
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
C4 Therapeutics, Inc. (C4T) announced that its management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 3, 2025, at 3:25 pm ET in Coral Gables, Florida. A live webcast and replay will be available on the company’s Investor Relations website. C4T is a clinical-stage biopharmaceutical company focused on targeted protein degradation science to develop innovative therapies for difficult-to-treat dise...
11-25 12:00
C4 Therapeutics files $400M mixed shelf offering
C4 Therapeutics (CCCC) has filed a shelf registration to offer up to $400M in securities. The offering may include common stock, preferred stock, debt securities, warrants, or units, in one or more co...
11-22 06:15
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
C4 Therapeutics reported a $125 million equity offering, extending its runway to late 2028. Notable achievements include strong Phase 1 data for cemsidomide in multiple myeloma with a 53% overall response rate, a collaboration with Pfizer to combine cemsidomide with elranatamab, and plans to initiate Phase 2 and Phase 1b trials in early 2026. The company remains focused on advancing cemsidomide's development and progressing its pipeline of target...
11-06 12:00
Precision Oncology Approaches Drive $312B Market Transformation
USA News Group News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, Oct. 17, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development accelerates ...
10-17 21:00
美股牛股 | PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；生物技术股WHWK涨超24%
PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；WHWK涨超24%，与Tempus AI建立战略伙伴关系，共同推进肿瘤研究领域发展>>
10-17 17:43
C4 Therapeutics prices $125M equity offering with warrants
C4 Therapeutics (NASDAQ:CCCC) priced an offering of 21.9M shares and 28.7M pre-funded warrants, each paired with Class A and Class B Warrants. Securities priced at $2.47/share or $2.4699/pre-funded wa...
10-16 19:27
C4 Therapeutics Presents Phase 1 Trial Data
An announcement from C4 Therapeutics ( ($CCCC) ) is now available. On October 1...
10-16 18:58
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
C4 Therapeutics announced the pricing of an underwritten offering to institutional investors, raising $125 million to fund the next phase of cemsidomide development in treating multiple myeloma, including a Phase 2 registrational trial with dexamethasone and a Phase 1b trial with elranatamab. The offering, led by RA Capital Management, includes shares of common stock and pre-funded warrants, with potential for an additional $225 million if all wa...
10-16 11:08
C4 Therapeutics Partners with Pfizer for Clinical Trial
The latest announcement is out from C4 Therapeutics ( ($CCCC) ). On October 1, ...
10-01 19:28
